CARLSBAD, Calif.,
Feb. 19, 2026 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:
36th Annual Oppenheimer Life Sciences Healthcare Conference
Format: Virtual fireside chat and one-on-one investor meetings
Presentation Date/Time: Thursday, February 26, 2026 at 12:00pm ET
Location: Virtual
46th Annual TD Cowen Healthcare Conference
Format: Hybrid presentation & fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, March 4th, 2026 at 11:50am ET
Location: Boston, MA
Leerink Global Healthcare Conference
Format: One-on-one investor meetings
Date: March 8-11, 2026
Location: Miami, FL
2026 Jefferies Biotech on the Beach Summit
Format: One-on-one investor meetings
Date: March 9-11, 2026
Location: Miami, FL
Barclays 28th Annual Global Healthcare Conference
Format: One-on-one investor meetings
Date: March 10-12, 2026
Location: Miami, FL
A live webcast of the presentations can be accessed by visiting the “For Investors” page on the Tyra Biosciences
website and will be available for replay following the event.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq:
TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA’s expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA’s lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low-grade upper tract urothelial carcinoma, intermediate risk non-muscle invasive bladder cancer and pediatric achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit
www.tyra.bio and engage with us on
LinkedIn.
Contact:
Amy Conrad
[email protected]
SOURCE Tyra Biosciences
Leave a Reply